Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Trial of ACE723, A Dual-Payload Antibody Drug Conjugate Targeting Glypican-3 (GPC-3), in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Who Have Failed or Progressed on Standard Immune Checkpoint Inhibitor-Containing Systemic Therapies

NCT07861425 is registered in ClinicalTrials.gov with Acepodia Biotech, Inc. as lead sponsor.

NCT NCT07861425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07861425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Trial of ACE723, A Dual-Payload Antibody Drug Conjugate Targeting Glypican-3 (GPC-3), in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Who Have Failed or Progressed on Standard Immune Checkpoint Inhibitor-Containing Systemic Therapies
Lead sponsor
Acepodia Biotech, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
May 31, 2030
Enrollment
70 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc), hepatocellular carcinoma metastatic, hepatocellular carcinoma non-resectable